UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5132-5139

2010

Volltextzugriff (PDF)

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1125-1132

2011

Volltextzugriff (PDF)

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

The lancet oncology, 2010-03, Vol.11 (3), p.275-280

2010

Volltextzugriff (PDF)

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1564-1571

2009

Volltextzugriff (PDF)

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4875-4882

2008

Volltextzugriff (PDF)

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

Blood, 2011-07, Vol.118 (1), p.28-36

2011

Volltextzugriff (PDF)

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

Journal of clinical oncology, 2007-10, Vol.25 (28), p.4431-4437

2007

Volltextzugriff (PDF)

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

Clinical cancer research, 2008-10, Vol.14 (20), p.6690-6696

2008

Volltextzugriff (PDF)

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

American journal of hematology, 2009-10, Vol.84 (10), p.650-656

2009

Volltextzugriff (PDF)

213 AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A226-A226

2021

Volltextzugriff (PDF)

RANKL inhibition in the treatment of bone metastases

Current opinion in supportive & palliative care, 2008-09, Vol.2 (3), p.197

2008

Volltextzugriff (PDF)

Cooperative interactions between paired domain and homeodomain

Development (Cambridge), 1996-09, Vol.122 (9), p.2639-2650

1996

Volltextzugriff (PDF)

Two Pax genes, eye gone and eyeless, act cooperatively in promoting Drosophila eye development

Development (Cambridge), 2003-07, Vol.130 (13), p.2939-2951

2003

Volltextzugriff (PDF)

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

Clinical cancer research, 2012-08, Vol.18 (16), p.4415-4424

2012

Volltextzugriff (PDF)

Crystal structure of a paired domain-DNA complex at 2.5 å resolution reveals structural basis for pax developmental mutations

Cell, 1995-02, Vol.80 (4), p.639-650

1995

Volltextzugriff (PDF)

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European journal of cancer (1990), 2012-11, Vol.48 (16), p.3082-3092

2012

Volltextzugriff (PDF)

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

British journal of haematology, 2013-05, Vol.161 (3), p.411-423

2013

Volltextzugriff (PDF)

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Supportive care in cancer, 2014-03, Vol.22 (3), p.679-687

2014

Volltextzugriff (PDF)

Lune/eye gone, a Pax-like protein, uses a partial paired domain and a homeodomain for DNA recognition

Proceedings of the National Academy of Sciences - PNAS, 1998-11, Vol.95 (23), p.13720-13725

1998

Volltextzugriff (PDF)

Abstract 585: AB-1015, a novel integrated circuit T cells containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, demonstrates specific and potent activity against ALPG/MSLN tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.585-585

2022

Volltextzugriff (PDF)

Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS7102-TPS7102

2015

Volltextzugriff (PDF)

Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS7101-TPS7101

2015

Volltextzugriff (PDF)

In vivo requirement for the paired domain and homeodomain of the paired segmentation gene product

Development (Cambridge), 1996-09, Vol.122 (9), p.2673-2685

1996

Volltextzugriff (PDF)

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Blood, 2013-11, Vol.122 (21), p.5239-5239

2013

Volltextzugriff (PDF)

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Blood, 2013-11, Vol.122 (21), p.1590-1590

2013

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(30)
Humans
(22)
Female
(18)
Middle Aged
(16)
Male
(14)
Denosumab
(13)
Oncology
(13)
Aged
(11)
Animals
(11)
Biological And Medical Sciences
(11)
Adult
(10)
Antibodies, Monoclonal, Humanized
(10)
Medical Sciences
(10)
Antibodies, Monoclonal - Therapeutic Use
(8)
Bone Neoplasms - Drug Therapy
(8)
Bone Neoplasms - Secondary
(8)
Tumors
(8)
Bone Density Conservation Agents - Therapeutic Use
(7)
Double-Blind Method
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

213 AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells

RANKL inhibition in the treatment of bone metastases

Cooperative interactions between paired domain and homeodomain

Two Pax genes, eye gone and eyeless, act cooperatively in promoting Drosophila eye development

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

Crystal structure of a paired domain-DNA complex at 2.5 å resolution reveals structural basis for pax developmental mutations

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Lune/eye gone, a Pax-like protein, uses a partial paired domain and a homeodomain for DNA recognition

Abstract 585: AB-1015, a novel integrated circuit T cells containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, demonstrates specific and potent activity against ALPG/MSLN tumors

Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis

Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis

In vivo requirement for the paired domain and homeodomain of the paired segmentation gene product

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Suchergebnisse filtern